Covista vs Universal Technical Institute
CVSA and UTI side by side, both in services-educational services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CVSA and UTI compare
Covista is the larger company, worth 3.2 times as much as Universal Technical Institute ($3.9B against $1.2B).
On earnings, Covista is cheaper: it trades at 16.1× trailing earnings, against 35.5× for Universal Technical Institute.
Covista grew revenue faster over the last twelve months (9.3% versus 9.1% for Universal Technical Institute).
Covista keeps more of each dollar of sales as profit, with a net margin of 12.8% compared with 3.9% at Universal Technical Institute.
Covista scores higher on the StockData Score (18 against 10 for Universal Technical Institute), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CVSA | UTI |
|---|---|---|
| Size and price | ||
| Market cap | $3.9B | $1.2B |
| Share price | $118.17 | $21.99 |
| Change, 1 year | 22.0% | −26.6% |
| Change, 5 years | 286% | 159% |
| Beta (5Y) | 0.84 | 0.75 |
| Employees | 510 | 4,100 |
| StockData Score | ||
| Total score | 18 (better) | 10 |
| Valuation score | 3 (better) | 0 |
| Growth score | 5 (better) | 3 |
| Performance score | 5 (better) | 4 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 16.1× (better) | 35.5× |
| P/S | 2.0× | 1.4× (better) |
| P/B | 2.8× (better) | 3.5× |
| EV/EBITDA | 10.6× (better) | 14.8× |
| P/FCF | 11.1× | – |
| PEG | 0.32 (better) | 0.81 |
| FCF yield | 9.0% (better) | −1.9% |
| Fair value | $119.25 | $14.05 |
| Margin of safety | 0.91% (better) | −56.5% |
| Growth | ||
| Revenue growth (TTM) | 9.3% (better) | 9.1% |
| Revenue growth, 5Y average | 16.8% | 22.7% (better) |
| Net income growth (TTM) | 1.8% (better) | −45.7% |
| EPS growth (TTM) | 9.6% (better) | −45.1% |
| EPS growth, 5Y average | 38.9% | 86.6% (better) |
| Profitability | ||
| Gross margin | 57.4% | – |
| Operating margin | 19.8% (better) | 5.0% |
| Net margin | 12.8% (better) | 3.9% |
| FCF margin | 17.7% (better) | −2.6% |
| Return on equity | 17.9% (better) | 10.5% |
| Return on invested capital | 17.8% (better) | 10.4% |
| Financial health | ||
| Debt / equity | 0.35 (better) | 0.46 |
| Net debt / EBITDA | 0.70 (better) | −0.12 |
| Interest coverage | 8.9× | 11.4× (better) |
| Current ratio | 0.81 | 1.30 (better) |
| Altman Z-score | 4.12 (better) | 2.72 |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | 8.0% | – |
| Shareholder yield | 8.0% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 113% |
| Held by insiders | 3.0% | 35.5% |
| Insider net buying, 12 months | −$6.6M (better) | −$104M |
| Short interest, % of float | 8.7% | 21.7% |
Go deeper
- CVSA stock overview
- CVSA income statement
- CVSA valuation and score
- UTI stock overview
- UTI income statement
- UTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.